Macrogenics, Inc.
21 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
15
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease (US 11,685,781) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 2 fees due Jan 9 to 11, 2027 · next Jan 9
- 1 fee due Feb 4, 2027The maintenance fee for Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use (US 9,096,877) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 3 fees due Apr 6 to 24, 2027 · next Apr 6
- 2 fees due May 19 to 21, 2027 · next May 19
- 1 fee due Jun 12, 2027The maintenance fee for Methods of Using Bispecific Molecules Having Immunoreactivity with PD-1 and CTLA-4 (US 11,840,571) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for LAG-3-binding molecules and methods of use thereof (US 11,858,991) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 4 fees due Sep 3 to 29, 2027 · next Sep 3
- 2 fees due Oct 28, 2027
- 1 fee due Nov 12, 2027The maintenance fee for Multi-Chain Polypeptide-Containing Tri-Specific Binding Molecules (US 10,647,768) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 13 US 12,760,106 Covalent Diabodies and Uses Thereof
- 2 terms have ended since Aug 23, 2026
- Oct 16 US 10,100,116 FcgammaRIIB-Specific Antibodies and Methods of Use Thereof · lapsed on the fee record
- Oct 4 US 11,459,394 Bispecific Binding Molecules That Are Capable of Binding CD137 and Tumor Antigens, and Uses Thereof · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,963,510 | Covalent Diabodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,098,125 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,254,747 | Covalent diabodies and uses thereof In force · USPTO record | In force | USPTO record | |
| US 10,711,069 | Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting In force · Medium confidence | In force | Medium confidence | |
| US 9,284,375 | Covalent Diabodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 7,700,100 | FcγRIIB fusion proteins and compositions thereof In force · USPTO record | In force | USPTO record | |
| US 9,708,408 | Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting In force · Medium confidence | In force | Medium confidence | |
| US 9,695,236 | BCR-complex-specific antibodies and methods of using same In force · USPTO record | In force | USPTO record | |
| US 10,479,831 | BCR-complex-specific antibodies and methods of using same In force · USPTO record | In force | USPTO record | |
| US 8,993,730 | BCR-Complex-Specific Antibodies and Methods of Using Same In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 53: 21 patents in force now held by others · 64 lapsed for an unpaid fee · 27 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
16 pending · 19 abandoned · 41 no status recorded
Showing 1 to 10 of 76, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/275,898 | Jul 21, 2025 | No status recorded | |
| 19/242,270 | Bi-Specific Monovalent Diabodies That Are Capable of Binding CD19 and CD3, and Uses Thereof | Jun 18, 2025 | Pending |
| 19/239,433 | Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use Thereof | Jun 16, 2025 | Pending |
| 18/915,947 | Oct 15, 2024 | No status recorded | |
| 18/794,328 | Aug 5, 2024 | No status recorded | |
| 18/746,758 | Jun 18, 2024 | No status recorded | |
| 18/442,857 | Bispecific Binding Molecules That Are Capable of Binding CD137 and Tumor Antigens, and Uses Thereof | Feb 15, 2024 | Abandoned |
| 18/394,869 | HER2/neu-Specific Antibodies and Methods of Using Same | Dec 22, 2023 | Pending |
| 18/499,658 | Methods of Using Bispecific Molecules Having Immunoreactivity with PD-1 and CTLA-4 | Nov 1, 2023 | Pending |
| 18/484,921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | Oct 11, 2023 | Pending |
10 of 76 applications shown.
Pro members see all 76 published applications.